Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
Authors
Keywords
-
Journal
BMC Pulmonary Medicine
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-13
DOI
10.1186/s12890-019-0937-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study
- (2019) David Bennett et al. LUNG
- Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients
- (2019) Gianluca Sambataro et al. RESPIRATORY MEDICINE
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis
- (2018) Kevin J. O'Brien et al. MOLECULAR GENETICS AND METABOLISM
- The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study
- (2018) Sebastiano Emanuele Torrisi et al. EUROPEAN RESPIRATORY JOURNAL
- Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial
- (2017) Jürgen Behr et al. BMC Pulmonary Medicine
- An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
- (2016) D. Khanna et al. JOURNAL OF RHEUMATOLOGY
- What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis
- (2016) S. Puglisi et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
- (2015) Paul W. Noble et al. EUROPEAN RESPIRATORY JOURNAL
- An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
- (2015) Aryeh Fischer et al. EUROPEAN RESPIRATORY JOURNAL
- Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT)
- (2015) Davide Colombi et al. PLoS One
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?
- (2014) Erica L. Herzog et al. Arthritis & Rheumatology
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
- (2013) William D. Travis et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search